ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 23724867

Nivolumab plus ipilimumab in advanced melanoma.

Wolchok JD and 23 others. N Engl J Med, 2013. Cited by 3,392 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Nivolumab plus ipilimumab in advanced melanoma. Papers, record 23724867. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23724867

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nivolumab plus ipilimumab in advanced melanoma.
PubMed
Journal
N Engl J Med
PubMed
Year
2013
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3,392
iCite
Relative citation ratio, by iCite
92.7
iCite
Revised in PubMed
2024-12-19
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wolchok JDJedd D
2Kluger HHarriet
3Callahan MKMargaret K
4Postow MAMichael A
5Rizvi NANaiyer A
6Lesokhin AMAlexander M
7Segal NHNeil H
8Ariyan CECharlotte E
9Gordon RARuth-Ann
10Reed KKathleen

1 to 10 of 24Source PubMed

See all 24 authors

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic AgentsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
CTLA-4 AntigenMajor topic
MelanomaMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Skin NeoplasmsMajor topic
Adult
Aged
Aged, 80 and over
Female
Humans
Infusions, Intravenous
Ipilimumab
Male
Middle Aged
Neoplasm Staging
Nivolumab
Young Adult

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K24 CA172123NCI NIH HHSUnited StatesK24CA172123PubMed and NIHNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER

Trials14

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01024231Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaDerived from the trialYesClinicalTrials.gov
NCT02460068A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain MetastasisBackgroundClinicalTrials.gov
NCT02661685Safety Study of Adoptive Transfer of Autologous IKDC-like CellsBackgroundClinicalTrials.gov
NCT02681302Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceBackgroundClinicalTrials.gov
NCT02766582Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary CancerBackgroundClinicalTrials.gov
NCT02846376Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantBackgroundClinicalTrials.gov
NCT02914405Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaResultsClinicalTrials.gov
NCT04441138Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLCBackgroundClinicalTrials.gov
NCT04663126Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic MelanomaBackgroundClinicalTrials.gov
NCT04765709Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLCBackgroundClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Erratum in31,442,371
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.
https://conductscience.org/library/papers/31442371PubMed
Comment in23,724,866Combination checkpoint blockade--taking melanoma immunotherapy to the next level.https://conductscience.org/library/papers/23724866PubMed
Comment in23,752,732From ASCO-targeted therapies: Anti-PD-1 approaches--important steps forward in metastatic melanoma.https://conductscience.org/library/papers/23752732PubMed

References20

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121,436,444Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science2011https://conductscience.org/library/papers/21436444PubMed
222,658,128Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med2012https://conductscience.org/library/papers/22658128PubMed
321,376,230Hallmarks of cancer: the next generation.Cell2011https://conductscience.org/library/papers/21376230PubMed
422,461,641Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.Sci Transl Med2012https://conductscience.org/library/papers/22461641PubMed
518,838,703Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.J Clin Oncol2008https://conductscience.org/library/papers/18838703PubMed
619,934,295Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.Clin Cancer Res2009https://conductscience.org/library/papers/19934295PubMed
716,227,604CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.Mol Cell Biol2005https://conductscience.org/library/papers/16227604PubMed
819,648,604What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma?Oncologist2009https://conductscience.org/library/papers/19648604PubMed
920,516,446Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.J Clin Oncol2010https://conductscience.org/library/papers/20516446PubMed
107,165,009Toxicity and response criteria of the Eastern Cooperative Oncology Group.Am J Clin Oncol1982https://conductscience.org/library/papers/7165009PubMed

1 to 10 of 20

See all 20 references

Cited by2,180

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,392 citations.

PMIDTitleJournalYearIn PapersSource
42,870,457Prostate Cancer Therapy via Inhibition of Negative Immune Regulation.Biomed Res Int2026https://conductscience.org/library/papers/42870457PubMed
42,856,433Engineered CTLA-4 targeting chimeras for targeted protein degradation and immune synapse reprogramming.bioRxiv2026https://conductscience.org/library/papers/42856433PubMed
42,795,023Management of Melanoma in Advanced Age: A Comprehensive Literature Review of Tumor Biology, Systemic Therapies and Geriatric Challenges.Cancers (Basel)2026https://conductscience.org/library/papers/42795023PubMed
42,750,591Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia.Oncoimmunology2026https://conductscience.org/library/papers/42750591PubMed
42,713,228Diagnostic Challenge of Immune Checkpoint Inhibitor-Induced Hypophysitis in Patient With Melanoma.Fed Pract2026https://conductscience.org/library/papers/42713228PubMed
42,687,049Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/42687049PubMed
42,669,662PI3K/AKT signaling pathway: molecular crossroads in tumorigenesis and therapeutic innovation.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42669662PubMed
42,662,577Unconventional guardians of the brain: MAIT cells as emerging players in glioblastoma immunity.Front Immunol2026https://conductscience.org/library/papers/42662577PubMed
42,646,677Bidirectional Interplay Between Tumor Vaccines and the Tumor Microenvironment: Mechanisms, Cold-to-Hot Conversion, and Combination Strategies.Vaccines (Basel)2026https://conductscience.org/library/papers/42646677PubMed
42,638,983Life-threatening anaphylactic shock induced by cadonilimab (AK104), a PD-1/CTLA-4 bispecific antibody: a case report.Front Pharmacol2026https://conductscience.org/library/papers/42638983PubMed

1 to 10 of 2,180

See all 2,180 cited by

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
GPT2,875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
SEMA4D10,507PubTator's text mininghttps://conductscience.org/library/genes/10507NCBI Gene
SLC17A526,503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
IPILIMUMABCHEMBL1789844Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1789844ChEMBL
NIVOLUMABCHEMBL2108738Results2https://conductscience.org/library/drugs/CHEMBL2108738ChEMBL
DINUTUXIMAB BETACHEMBL5315068Results1https://conductscience.org/library/drugs/CHEMBL5315068ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23724867

GET https://conductscience.org/api/papers/v1/23724867/authors?page=2

API referenceFor AI assistants